These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37491519)
41. Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab. Umscheid JH; Nevil C; Vasudeva R; Ali MF; Agasthya N Case Rep Pediatr; 2021; 2021():8053246. PubMed ID: 34812294 [TBL] [Abstract][Full Text] [Related]
42. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Walsh PR; Johnson S Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046 [TBL] [Abstract][Full Text] [Related]
43. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224 [TBL] [Abstract][Full Text] [Related]
44. Prodromal Phase of Hemolytic Uremic Syndrome Related to Shiga Toxin-Producing Escherichia coli: The Wasted Time. Balestracci A; Meni Battaglia L; Toledo I; Martin SM; Alvarado C Pediatr Emerg Care; 2021 Oct; 37(10):e625-e630. PubMed ID: 31290797 [TBL] [Abstract][Full Text] [Related]
49. Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome. Dinh A; Anathasayanan A; Rubin LM Am J Health Syst Pharm; 2015 Jan; 72(2):117-20. PubMed ID: 25550134 [TBL] [Abstract][Full Text] [Related]
52. Diagnosis and Treatment for Shiga Toxin-Producing Liu Y; Thaker H; Wang C; Xu Z; Dong M Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668830 [TBL] [Abstract][Full Text] [Related]
53. Genome-wide association study of hemolytic uremic syndrome causing Shiga toxin-producing Escherichia coli from Sweden, 1994-2018. Matussek A; Mernelius S; Chromek M; Zhang J; Frykman A; Hansson S; Georgieva V; Xiong Y; Bai X Eur J Clin Microbiol Infect Dis; 2023 Jun; 42(6):771-779. PubMed ID: 37103716 [TBL] [Abstract][Full Text] [Related]
54. Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland. Rastawicki W; Śmietańska K; Rokosz-Chudziak N; Wołkowicz T Lett Appl Microbiol; 2020 Jun; 70(6):440-446. PubMed ID: 32270510 [TBL] [Abstract][Full Text] [Related]
55. Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. Santangelo L; Netti GS; Torres DD; Piscopo G; Carbone V; Losito L; Milella L; Lasorella ML; Conti P; Gagliardi D; Chironna M; Spadaccino F; Bresin E; Trabacca A; Ranieri E; Giordano M Ital J Pediatr; 2021 Sep; 47(1):181. PubMed ID: 34488831 [TBL] [Abstract][Full Text] [Related]
56. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996-2006. Espié E; Grimont F; Mariani-Kurkdjian P; Bouvet P; Haeghebaert S; Filliol I; Loirat C; Decludt B; Minh NN; Vaillant V; de Valk H Pediatr Infect Dis J; 2008 Jul; 27(7):595-601. PubMed ID: 18520972 [TBL] [Abstract][Full Text] [Related]
58. Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control study. Doulgere J; Otto B; Nassour M; Wolters-Eisfeld G; Rohde H; Magnus T; Wagener C; Streichert T BMJ Open; 2015 Mar; 5(3):e005659. PubMed ID: 25757942 [TBL] [Abstract][Full Text] [Related]
59. Incidence and etiology of hemolytic-uremic syndrome in children in Norway, 1999-2008--a retrospective study of hospital records to assess the sensitivity of surveillance. Jenssen GR; Hovland E; Bjerre A; Bangstad HJ; Nygard K; Vold L BMC Infect Dis; 2014 May; 14():265. PubMed ID: 24884396 [TBL] [Abstract][Full Text] [Related]